Transcriptomics

Dataset Information

0

Cyclodextrin-derived Nano-medicine Suppresses the Progression of Colorectal Cancer


ABSTRACT: The malignancy of colorectal cancer is connected with inflammation, which poses great therapeutic challenges. To integratetherapeutic targets with anti-inflammation strategy, wedeveloped a biocompatible, non-covalent channel-type nanoparticles that was fabricated through host-guest complexation and multiple assemble of mannose-modified ?-cyclodextrin (M-?-CD) with Regorafenib (RG), denoted as RG@M-?-CD. For in vivo application, the channel-type formulation optimized the pharmacokinetics and bio-distribution of RG. In colitis-associated cancer (CAC) and CT26 models, RG@M-?-CD was proven to be a targeted, safe and effective anti-tumor nanomedicine that suppressed tumor cells proliferation, lesioned neovascularization, and attanuated inflammation. To investigate the therapeutic mechanism of RG@M-?-CD nanomedicine, small pieces of colon tissue with tumors from control group and treatment group were used to perform the microarray for gene expression anaylsis. The RGnanomedicine is constructed through the host-guest assemble between mannose-modified ?-cyclodextrin (M-?-CD) and TKI Regorafenib (RG). With multiple assemble, the host-guest system is transformed into nanoparticle, denoted as RG@M-?-CD (or RG nanomedicine).

ORGANISM(S): Mus musculus

PROVIDER: GSE157993 | GEO | 2020/09/24

REPOSITORIES: GEO

Similar Datasets

2015-02-15 | GSE63332 | GEO
2017-07-01 | GSE47696 | GEO
2015-02-15 | E-GEOD-63332 | biostudies-arrayexpress
2015-11-15 | GSE42312 | GEO
2013-12-02 | E-GEOD-51135 | biostudies-arrayexpress
2024-02-13 | GSE255332 | GEO
2016-09-29 | PXD002882 | Pride
2013-12-02 | GSE51135 | GEO
2024-02-15 | GSE255604 | GEO
2016-05-06 | GSE67013 | GEO